Premium
FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY
Author(s) -
Flinn I.,
Jagt R.,
Chang J.,
Wood P.,
Hawkins T.,
MacDonald D.,
Trotman J.,
Simpson D.,
Kolibaba K.,
Issa S.,
Hallman D.,
Chen L.,
Burke J.M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_130
Subject(s) - medicine , rituximab , vincristine , prednisone , chop , hazard ratio , gastroenterology , mantle cell lymphoma , cyclophosphamide , confidence interval , lymphoma , surgery , oncology , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom